Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2003

View Archived Issues

DPP-IV inhibitors in Probiodrug development pipeline

Novel series of melatonin receptor agonists identified by BMS team

Novartis patent covers new antitumor discodermolide analogues

New iNOS inhibitors and their use in Parkinson's disease described by Aventis

Amidine-based factor VIIa inhibitors in early development at Eisai

Noncalcemic vitamin D analogue for psoriasis, cancer, etc., discovered by WARF team

Mandelate salts of 5-HT2A/5-HT2C antagonists with enhanced stability

Oncofetal protein validated as a potential target for lung cancer immunotherapy

Axcan to support phase II studies of Photofrin PDT in cholangiocarcinoma

BioPort completes purchase of Antex Biologics assets

rFXIII enters third clinical study, gains orphan drug status

Scynexis and Molecular Engines Laboratories collaborate on anticancer therapeutic discovery

Fast track designation for CA4P in anaplastic thyroid cancer

Intranasal apomorphine enters new phase II study in erectile dysfunction

GenOdyssee grants development and commercialization license to Debiopharm

CPMP grants positive opinion on new indication for Actos

New GenoMed trial for osteoporosis

Ciprofloxacin GR enters phase III program for urinary tract infections

First phenserine trial under way in phase IIb/III program in Alzheimer's disease

HER-2/neu vaccine enters phase I trial for breast cancer

APA presentations on indiplon further support its safety and efficacy in insomnia

Transgene offers clinical progress report

Piperine as a safe and effective treatment for vitiligo available from BTG

VNP-40101M evaluated in phase I trial in hematological malignancies

Interim findings from ongoing phase I trial of OncoVEX(GM-CSF)

More on Enanta's ciclosporin analogues with improved toxicity profiles

Cetuximab, a significant advance in cancer therapy, a focus of discussion at ASCO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...